Abbott Laboratories’ CFO, Philip P. Boudreau, made an open-market purchase of 2,200 shares on April 23, 2026, paying $91.50 per share for a total of about $201,300. Insider buys made with personal funds in the open market tend to draw attention because they are voluntary and reflect a decision to increase direct exposure to the stock at prevailing prices. Boudreau is both Executive Vice President and Chief Financial Officer, a role that typically carries deep visibility into the company’s financial performance, cash flow, and near-term risks. While a $201,000 purchase is modest relative to Abbott’s overall market value, it is meaningful as a personal commitment and stands out because CFO purchases are less common than routine insider sales. This trade also matters in context: it follows a period in March 2026 when other Abbott insiders reportedly sold shares and completed non-open-market transactions, some at higher prices than this purchase. In the last 30 days, this filing is the only reported insider transaction at ABT, making it a notable shift in the recent activity mix toward buying.